Liver Cancer
Advertisement
Drs. Finn and Yopp discuss adjuvant therapy in HCC following surgical resection in a review of data from IMbrave050.
Drs. Finn and Yopp discuss the IMbrave050 study for early-stage HCC, including the trial design, results, and implications.
A recent study showed evidence that HBV infection facilitates drug resistance in cancer treatment medications.
The FDA has approved nivo for subcutaneous injection for all solid tumors for which nivo is indicated as a monotherapy.
SBRT with sorafenib is shown to be associated with a clinically important but not statistically significant improved OS rate.
Rising HCC mortality rates in the US highlight stark disparities across age, sex, race, and liver disease etiologies.
Kaplan-Meier curves showed that patients with high TBS had significantly decreased OS and increased recurrence rates.
A recent analysis reviewed patient-level data to identify the relationship between pathological response and relapse.
Repeated use of TACE can impair liver function and stimulate tumor angiogenesis.
Dr. Richard Finn provides an overview of the key studies in liver cancer from ESMO 2024.
Dr. Weinberg provides a recap of all of the GI oncology data of practice-changing potential presented at ESMO 2024.
HIMALAYA found tremelimumab plus durvalumab to significantly improve overall survival over sorafenib alone.
FDA approval comes after the IMscin001 trial, an open-label, multi-center, international analysis of adult patients.
A study compared the outcomes of patients with HCC who underwent upfront surgical resection versus neoadjuvant immunotherapy.
Dr. Amit Mahipal discusses a recent study on atezolizumab plus bevacizumab as a first-line treatment for HCC.
Amezalpat is a PPAR⍺ antagonist that modulates immune suppressive cells and angiogenesis in the tumor microenvironment.
The FDA's decision to accept the sBLA is based on the encouraging results of the phase 3 CheckMate-9DW study.
Dr. Dan Kaufman discusses recent research on TGF-β and how it is linked to the development of HCC.
TACE may not be an optimal treatment strategy for patients with extensive tumor bulk or impaired liver function.
The study’s primary end point was overall survival in the inverse probability of treatment weighting.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.